Autobio Diagnostics Co (SHSE:603658) Cyclically Adjusted Revenue per Share: ¥5.96 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603658 Autobio Diagnostics Co Ltd SHSE:603658
95 GF Score
Price ¥32.71
GF Value ¥40.27
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Autobio Diagnostics Co Cyclically Adjusted Revenue per Share?

Autobio Diagnostics Co SHSE:603658 +0.99% 95 Cyclically Adjusted Revenue per Share is ¥5.96 as of Jun. 2026. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.27 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Autobio Diagnostics Co's adjusted revenue per share for the three months ended in Jun. 2026 was ¥1.883. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥5.96 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Autobio Diagnostics Co's average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-03), Autobio Diagnostics Co's current stock price is ¥32.71. Autobio Diagnostics Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥5.96. Autobio Diagnostics Co's Cyclically Adjusted PS Ratio of today is 5.49.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Autobio Diagnostics Co was 11.27. The lowest was 4.92. And the median was 7.47.


Autobio Diagnostics Co  (SHSE:603658) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Autobio Diagnostics Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32.71/5.96
=5.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Autobio Diagnostics Co was 11.27. The lowest was 4.92. And the median was 7.47.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Autobio Diagnostics Co Cyclically Adjusted Revenue per Share Related Terms


Autobio Diagnostics Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Autobio Diagnostics Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autobio Diagnostics Co Cyclically Adjusted Revenue per Share Chart

Autobio Diagnostics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 5.26 5.69

Autobio Diagnostics Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 5.53 5.69 5.84 5.96

SHSE:603658 vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Autobio Diagnostics Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autobio Diagnostics Co Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Autobio Diagnostics Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603658
95GF Score
Autobio Diagnostics Co Ltd SHSE:603658
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autobio Diagnostics Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Autobio Diagnostics Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.883/116.0564*116.0564
=1.883

Current CPI (Jun. 2026) = 116.0564.

Autobio Diagnostics Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.520 102.400 0.589
201612 0.514 102.600 0.581
201703 0.442 103.200 0.497
201706 0.638 103.100 0.718
201709 0.722 104.100 0.805
201712 0.756 104.500 0.840
201803 0.766 105.300 0.844
201806 0.795 104.900 0.880
201809 0.934 106.600 1.017
201812 1.040 106.500 1.133
201903 1.010 107.700 1.088
201906 1.142 107.700 1.231
201909 1.313 109.800 1.388
201912 1.432 111.200 1.495
202003 1.000 112.300 1.033
202006 1.154 110.400 1.213
202009 1.508 111.700 1.567
202012 1.677 111.500 1.746
202103 1.382 112.662 1.424
202106 1.464 111.769 1.520
202109 1.746 112.215 1.806
202112 1.833 113.108 1.881
202203 1.760 114.335 1.787
202206 1.771 114.558 1.794
202209 2.094 115.339 2.107
202212 1.987 115.116 2.003
202303 1.798 115.116 1.813
202306 1.831 114.558 1.855
202309 1.948 115.339 1.960
202312 2.088 114.781 2.111
202403 1.881 115.227 1.895
202406 2.004 114.781 2.026
202409 1.949 115.785 1.954
202412 1.916 114.893 1.935
202503 1.734 115.116 1.748
202506 1.952 114.907 1.972
202509 1.780 115.471 1.789
202512 1.944 115.832 1.948
202603 1.720 116.303 1.716
202606 1.883 116.056 1.883

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥5.96 mean?
Autobio Diagnostics Co (SHSE:603658) has a Cyclically Adjusted Revenue per Share of ¥5.96 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Autobio Diagnostics Co and its competitors.
Is Autobio Diagnostics Co's Cyclically Adjusted Revenue per Share too high?
Autobio Diagnostics Co's current Cyclically Adjusted Revenue per Share is ¥5.96. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Autobio Diagnostics Co's Cyclically Adjusted Revenue per Share of ¥5.96 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Autobio Diagnostics Co and its competitors. Autobio Diagnostics Co's current Cyclically Adjusted Revenue per Share is ¥5.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.27, compared to a current price of ¥32.71 — trading 18.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥5.96. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current Cyclically Adjusted Revenue per Share is ¥5.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?

Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued. The current stock price of ¥32.71 is trading 18.8% below its estimated GF Value™ of ¥40.27. GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.

Key valuation signals for SHSE:603658:

  • Cyclically Adjusted Revenue per Share: ¥5.96
  • GF Value™: ¥40.27 vs. price of ¥32.71 (18.8% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Autobio Diagnostics Co Business Description

Address No. 199, Jingkai 15th Street, Economic and Technological Development Zone, Zhengzhou, CHN, 450016
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score

Get the complete analysis for SHSE:603658

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥32.71
Price
¥40.27
GF Value